Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 44Genitourinary 14Head & Neck 5Thoracic 4Dermatologic 4Gynecologic 3Tumor-Agnostic 2Breast 2

Conditions

Triple Negative Breast Neoplasms 1Advanced Breast Cancer 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Electroporation × Breast × Clear all
NCT02531425 2023-05-15

TNBC

OncoSec Medical Incorporated

Phase 1 Completed
10 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03240224 2019-01-25

Bioinformation Therapy for Breast Cancer

Fuda Cancer Hospital, Guangzhou

Phase 2/3 Completed
120 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡